What the Purdue Pharma Case Teaches Us About Reputational Risk

In this ISSUE

DIA Europe: Patients Have Their Say. Now for the Doctors?

Maximizing the Rare Chance of Launch Success with Orphan Drugs

Data as Currency: The Value of Longitudinal Data for Pharma

Top Story

What the Purdue Pharma Case Teaches Us About Reputational Risk

Purdue Pharma and its corporate leadership featured prominently in the media recently as litigation mounts over their sales and marketing of Oxycontin. Dr. Nir Kossovsky offers some observations about the lessons this situation provides for all corporate leaders responsible for their companies' reputations
… /Read more/

Regulatory

FDA Big Winner in Final Congressional Budget Agreement

FDA came away with the largest boost in its annual budget in a decade as part of the final spending package approved by Congress last week. Jill Wechsler reports
… /Read more/

Pricing

Unsupported Price Increases: A New Focus for ICER

Among the new acronyms to watch is UPI, or unsupported price increase, recently coined by ICER as part of its new workstream to explore price increases for both branded and generic drugs in the US. Leela Barham reports
… /Read more/

Global

China: A Change in Attitude

How innovation growth has upped the pressure on China to compete globally, forcing upgrades in regulatory, quality, and standards
… /Read More/

Q&A

Regulatory Reform in China

Dr. Lingshi Tan, a director at DIA, and chairman and CEO of Shanghai-based CRO dMed Company Limited, discusses the nation's regulatory evolution and opportunities for its government to strengthen collaborations with FDA and other global agencies
… /Read More/

The Pharm Exec Podcast: China's Pharma Growth

The Pharm Exec editors talk with David Shao, CEO of Yisheng Biopharma, about what’s driving China's exploding pharma and biotech industries, as well as the country’s push to become a global life science leader
… /Click here to listen/

Calendar

/ February 26–27: 12^th Hub and SPP Model Optimization /

Philadelphia, PA

/ March 4–6: 20^th Annual Patient Assistance and Access Programs – PAP 2019 /

Baltimore, MD

/ March 12–13: Pharmaceutical Compliance Congress Asia /

Shanghai, China

/ March 12–13: e-Rx and EHR 2019 /

Philadelphia, PA

/ March 12–14: 17^th Annual eyeforpharma Barcelona /

Barcelona, Spain

/ March 18–21: DCAT Week '19 /

New York City, NY

/ March 20–22: 15^th Life Sciences Accounting and Reporting Congress /

Philadelphia, PA

/ March 20–March 21: Partnering with IDNs Biopharma Strategy Summit West /

Scottsdale, AZ

/ March 27–28: 12^th Annual Expanded Access Programs /

Philadelphia, PA

/ June 12–13: Rare Disease Innovation and Partnering Summit /

Boston, MA

Industry update

//Aravive (Houston, TX) promoted Gail McIntyre, PhD, DABT to Chief Scientific Officer. // Achillion Pharmaceuticals (New Haven, CT) appointed Brian Di Donato as Senior Vice President and Chief Financial Officer. // Mundipharma (Cambridge, UK) appointed Patrice Grand to the position of European Director of Corporate Communications. // Sanofi (Paris, France) appointed Ameet Nathwani, MD, as Chief Digital Officer, in addition to his current role as Executive Vice President, Chief Medical Officer.

advertise with us / print subscribe / digital subscribe / visit pharmexec.com